Overview
Hexarelin is one of the most potent synthetic growth hormone releasing peptides (GHRPs), producing the strongest GH release of any GHRP. It is a hexapeptide analog of GHRP-6 with a methylated tryptophan residue that increases its potency. Beyond GH release, hexarelin has notable cardioprotective properties, acting directly on cardiac tissue independent of GH. It was studied in clinical trials for heart failure.
Mechanism of action
Hexarelin binds to the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, stimulating robust GH release. It produces the highest GH spike of any GHRP (up to 7x baseline). It also activates cardiac GHS receptors (GHS-R1a in cardiomyocytes), providing direct cardioprotection: reducing cardiac fibrosis, improving ventricular function, and protecting against ischemia-reperfusion injury. Unlike Ipamorelin, hexarelin does increase cortisol and prolactin at higher doses.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| GH release / body composition | subcutaneous | 100–200 mcg | 2-3x daily | Inject on empty stomach. GH response desensitizes with continuous use — cycle 4-8 weeks on, 4 weeks off. Keep doses moderate to limit cortisol/prolactin effects. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Clinical studies confirm potent GH release (5-7x baseline) with dose-dependent response. Phase II heart failure trials showed improved cardiac function (increased LVEF, reduced wall stress) independent of GH effects. Cardioprotective effects demonstrated in post-MI patients and animal models. GH response attenuates with chronic use (desensitization of GHS-R1a), recommending cyclic use. Side effects include increased cortisol and prolactin at doses above 2mcg/kg, appetite stimulation, and water retention.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Hexarelin for synergistic effects.
Legal status
Not FDA-approved. Was in clinical development for heart failure (Europeptides). Available as a research peptide. Not scheduled.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.